Form 4: Castle Biosciences Director, Daniel Bradbury, Reports Stock Unit Vesting
SEC Form 4 Filing
Director Daniel Bradbury reported the vesting of 8,636 Restricted Stock Units (RSUs) into common stock of Castle Biosciences on May 25, 2024.
Summary
- On May 25, 2024, Daniel Bradbury, a director of Castle Biosciences, Inc. (CSTL), had 8,636 Restricted Stock Units (RSUs) vest.
- Each RSU represents the right to receive one share of Castle Biosciences' common stock.
- The RSUs vested in full on the one-year anniversary of the grant date, which was May 25, 2024.
- Following the transaction, Bradbury directly owns 13,291 shares of Castle Biosciences common stock.
Sentiment
Score: 7
Explanation: The document is a standard SEC filing related to stock vesting, which is generally neutral. The vesting suggests continued service and alignment with company goals, which is mildly positive.
Positives
- The vesting of RSUs indicates that Bradbury has met the conditions set by the company, likely related to his continued service as a director.
Industry Context
This is a routine disclosure related to executive compensation and is typical for publicly traded companies.
Stakeholder Impact
- The vesting of RSUs has a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/25/2024 | Date of earliest transaction (RSU vesting) |
| 05/25/2024 | RSUs vested in full on the one-year anniversary of the date of grant |
| 05/29/2024 | Date of signature by Attorney-in-fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.